BREAST CANCER

The risk of progression or death was reduced by 40% with the combination of nab-paclitaxel and carboplatin compared with 2 other chemotherapy doublets as a frontline therapy for patients with metastatic triple-negative breast cancer.

Alberto Montero, MD, discusses the significance of the PERTAIN study in estrogen-positive, HER2-positive patients.

Sarah Hurvitz, MD, gives an overview of the neoMONARCH trial in hormone receptor-positive, HER2-negative breast cancer.

Neoadjuvant chemotherapy with nanoparticle albumin-bound nab-paclitaxel has demonstrated substantial activity across major subgroups of breast cancer, a meta-analysis of clinical trials showed.

Denise A. Yardley, MD, discusses the tnAcity clinical trial results and current role of nab-paclitaxel in TNBC, as well as the potential for using nab-paclitaxel in combination with immunotherapy in this setting.

The combination of the Fc-modified monoclonal antibody margetuximab with chemotherapy may offer a new treatment option for patients with HER2-positive metastatic breast cancer.

Cecile Pizot, a biostatistician in Epidemiology at the International Prevention Research Institute, discusses a study that examined breast cancer mortality rates across 47 countries.

Steven Buechler, PhD, Department of Applied and Computational Mathematics and Statistics at the University of Notre Dame, discusses independent validation of the EarlyR gene signature in the Breast International Group 1-98 study.

The results of a recent randomized study showed anti-HER2 DC1 vaccination to be a safe and immunogenic treatment to induce tumor-specific T-cell responses in patients with HER2-positive breast cancer.

While mutations of the <em>BRCA</em> gene can increase a woman&rsquo;s chances of developing breast and ovarian cancers, the presence of the gene made no difference in survival for women aged 40 years or younger who were diagnosed with early-stage breast cancer.

Denise Yardley, MD, senior investigator at the Sarah Cannon Research Institute, discusses the phase II tnAcity trial in triple-negative breast cancer.

In a recent early-stage HER2-positive breast cancer trial, prophylactic treatment with the combination of loperamide and budesonide reduced the rate of grade 3 diarrhea associated with neratinib to 15%.

Sibylle Loibl, MD, PhD,&nbsp;co-chair of the German Breast Group and associate professor at the University of Frankfurt, discusses the most recent subanalysis of the GeparSepto trial in luminal, triple-negative, and HER2+ breast cancer.

Sibylle Loibl, MD, PhD, discusses the most recent subanalysis of the GeparSepto trial, how the drugs match up in terms of toxicities, and a separate set of data looking at patients with breast cancer who are also pregnant.

Julia White, MD, discusses the upcoming phase II trial, the toxicities associated with the treatment, and the potential for control of these metastases. According to White, the trial is still accruing its 143 patients.

Sara Tolaney, MD, MPH, associate clinical research director of Breast Oncology at the Dana-Farber Cancer Institute in Boston, discusses a clinical trial investigating pembrolizumab in combination with eribulin in triple-negative breast cancer.&nbsp;

Paul Kelly Marcom, MD, discusses the future landscape of HR-positive breast cancer, highlighting the influence of CDK4/6 inhibitors and targeted agent/endocrine therapy combinations.

Patients with breast cancer who received radiation therapy following a mastectomy reported increased complications and lower satisfaction, according to the results of a large, multicenter study.

Julia White, MD, professor of Radiation Oncology, Ohio State University, discusses a phase II study of whole brain radiotherapy with concurrent lapatinib in patients with brain metasteses from HER2-positive breast cancer.

Mark D. Pegram, MD, director of the Breast Cancer Oncology Program, Stanford Women&rsquo;s Cancer Center, co-director of Molecular Therapeutics Program, Stanford Medicine, discusses a phase II trial looking at ONT-380 in HER2+ breast cancer.&nbsp;

The FDA has granted a priority review to a supplemental new drug application supporting the conversation of the accelerated approval of palbociclib to a full approval for use in combination with letrozole as a frontline treatment for postmenopausal women with ER-positive, HER2-negative metastatic breast cancer.

The FDA has approved the marketing of AeroForm, a new system for soft tissue expansion in 2-stage breast reconstruction following mastectomy, and in the treatment of underdeveloped breasts and soft tissue deformities.

The phase II HERMIONE trial was halted after the antibody-drug conjugate MM-302 combined with trastuzumab (Herceptin) failed to improve progression-free survival (PFS) versus chemotherapy plus trastuzumab in patents with HER2-positive metastatic breast cancer who had previously received trastuzumab, pertuzumab (Perjeta), and ado-trastuzumab emtansine (T-DM1, Kadcyla).

According to results presented during the 2016 San Antonio Breast Cancer Symposium,&nbsp;neoadjuvant combination of CDK4/6 inhibitor abemaciclib plus anastrazole may represent a novel therapeutic option for patients with hormone receptor (HR)-positive, HER2-negative early breast cancer.

The 2017 Miami Breast Cancer Conference, to be held March 9 to 12 at the Fontainebleau Miami Beach, welcomes an expanded group of program chairs, and a newly established curriculum committee made up of a multidisciplinary group of breast cancer specialists.